# Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function

> **NCT01686932** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01686932
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2016-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01686932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01686932, "Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01686932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*